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Developing adeno-associated viral (AAV)–mediated gene 
therapy for hemophilia A (HA) has been challenging due 
to the large size of the factor VIII (FVIII) complementary 
DNA and the concern for the development of inhibitory 
antibodies to FVIII in HA patients. Here, we perform a 
systematic study in HA dogs by delivering a canine FVIII 
(cFVIII) transgene either as a single chain or two chains in 
an AAV vector. An optimized cFVIII single chain delivered 
using AAV serotype 8 (AAV8) by peripheral vein injection 
resulted in a dose-response with sustained expression of 
FVIII up to 7% (n = 4). Five HA dogs administered two-
chain delivery using either AAV8 or AAV9 via the portal 
vein expressed long-term, vector dose–dependent levels 
of FVIII activity (up to 10%). In the two-chain approach, 
circulating cFVIII antigen levels were more than fivefold 
higher than activity. Notably, no long-term immune 
response to FVIII was observed in any of the dogs (1/9 
dogs had a transient inhibitor). Long-term follow-up of the 
dogs showed a remarkable reduction (>90%) of bleeding 
episodes in a combined total of 24 years of observation. 
These data demonstrate that both approaches are safe 
and achieve dose-dependent therapeutic levels of FVIII 
expression, which supports translational studies of AAV-
 mediated delivery for HA.
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IntroductIon
Hemophilia A (HA) is an X-linked bleeding disorder character-
ized by deficiency in factor VIII (FVIII), a key component in 
the coagulation cascade.1 Current treatment for HA is by pro-
tein replacement either in response to bleeds or as a preventative 
therapy. Prophylaxis in children with severe HA requires three to 
four injections per week; however, this approach does not prevent 
breakthrough bleedings that occur at times when FVIII levels are 
subtherapeutic. A recent study demonstrated that children with 
severe HA receiving prophylactic treatment with recombinant 
FVIII exhibit fewer joint bleeds and less joint damage than those 
on high-dose protein therapy on demand.2 However, there is no 
consensus yet on the long-term impact of prophylaxis and whether 
adults would benefit from similar regimens. Moreover, differences 
in the underlying joint status and pharmacoeconomics further 
complicate the management of the disease in adult populations.
Therapeutic strategies based on cell or gene therapy for the 
management of HA have aimed at sustained expression of ther-
apeutic levels of FVIII that provides the benefits of prophylaxis 
without the pitfalls of replacement therapy. Collective experience 
by our and other groups demonstrate the potential of adeno-
 associated virus (AAV) vectors to ensure sustained expression 
of clotting factors either by liver- or skeletal muscle–directed 
strategies.3–6 Although the levels of FVIII required for therapeu-
tic effect are 50-fold lower than for factor IX (FIX), there are two 
major differences from a gene therapy perspective. The first is the 
limited packaging capacity of AAV for the large FVIII complemen-
tary DNA and the second is the high risk of immune responses to 
the neotransgene that is anticipated with protein-based therapy 
and potentially with any novel therapy for HA.
The canine HA model mimics the severe human disease at 
molecular and phenotypic levels and thus provides an ideal 
model for preclinical studies.7 Studies in mouse models have 
demonstrated efficient liver transduction of AAV serotype 8 
(AAV8) or AAV9.5,8–11 We have previously reported some initial 
studies using AAV8 and AAV9 (ref. 5) and another group has 
reported the use of AAV8 in HA dogs.6 In the canine HA model, 
we reported that coadministration of AAV8 or AAV9 encoding 
separately the heavy and light chains of the cFVIII was safe and 
resulted in long-term, dose-dependent expression of therapeutic 
levels of cFVIII.5 However, whether the expression of relatively 
large amounts of nonfunctional protein could affect the immune 
responses to protein replacement with FVIII protein and/or 
induce damage of the target tissue, as reported in other models 
of FVIII expression,12 raised safety concerns. Jiang et al.6 further 
reported that sustained expression of cFVIII as a single chain 
by AAV vectors from serotypes 2, 6, and 8 was only effective in 
some HA dogs and there was no clear vector-dose dependency on 
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FVIII expression, a fact not observed for FIX expression in large 
animal models of hemophilia B.13–15
The limitations of these two studies were the small numbers 
of animals for each vector serotype, variable vector dosage, the 
use of two different strains of dogs and two different delivery 
approaches. Here, we report a study in HA dogs in which we sys-
tematically compare AAV vectors encoding the cFVIII gene by a 
single- or two-chain approach by hepatic or noninvasive periph-
eral vein delivery. We demonstrate that both strategies are effica-
cious, prevent >90% of spontaneous bleeding episodes, and have 
no evidence for toxicity. In addition, there is no evidence of long-
term immune responses to FVIII that was sustained upon chal-
lenges with recombinant cFVIII. These data will form the basis for 
clinical studies in humans with severe HA.
results
single-chain cFVIII delivery in HA mice
Previously, we described a 5.6-kb single-chain B-domain-deleted 
cFVIII (cFVIII-BDD) construct that cannot package efficiently 
into an AAV vector resulting in poor vector yield.10 We sought to 
improve the packaging efficiency of the cFVIII-BDD constructs 
by minimizing the regulatory elements in order to shorten the 
cFVIII transgene construct. Ten novel single-chain constructs 
(Supplementary Figure S1) utilizing the insulin-like growth 
factor–binding protein promoter (IGFBP) or the hepatic control 
region-human α-1 antitrypsin enhancer-promoter (HCR-hAAT) 
were systematically compared in vitro in HepG2 cells and by 
hydrodynamic infusion in HA mice (Supplementary Figure S2). 
AAV vectors were generated from the three cFVIII-BDD con-
structs that were <5.3 kb (Figure 1a) and expressed cFVIII at 
levels comparable to those observed with our 5.6 kb cFVIII-BDD 
construct. HA mice were treated with 5 × 1010 vector genomes/
mouse of the AAV8-cFVIII-BDD constructs and compared to the 
original 5.6 kb construct (Figure 1b). The cFVIII constructs with 
the IGFBP and HCR-hAAT promoters are comparable in terms 
of maximum FVIII expression levels that can be achieved. These 
constructs are both 5.2 kb, our goal for minimizing the transgene 
size, and gave similar yields of vector (data not shown). Thus, we 
concluded that either the IGFBP or HCR-hAAT promoter would 
be a good candidate for translating to larger animal models.
correction of the HA phenotype after single-chain 
delivery of FVIII in HA dogs
Since the IGFBP and HCR-hAAT promoter constructs expressed 
similar levels of cFVIII-BDD in the mouse studies (Figure 1) and 
the hAAT promoter has been used clinically in phase I clinical 
studies for AAV-FIX,15,16 the HCR-hAAT-cFVIII construct was 
selected for studies in the HA dog (Figure 2a). No significant 
differences were observed between AAV8 and AAV9 in our pre-
vious studies;5 thus, we used AAV8 to deliver the single-chain 
cFVIII by peripheral vein infusion. Data in mice and nonhuman 
primates suggest that peripheral vein delivery of AAV8 for FIX 
expression is comparable to hepatic delivery.5,15 Thus, we focused 
on the use of AAV8 by intravenous injection to simplify the clini-
cal applicability of this approach. In contrast to portal vein deliv-
ery, peripheral vein infusion is minimally invasive, well-tolerated 
and does not require protein treatment at the time of vector 
infusion. Dogs M06 and M50 receiving the high vector dose 
(4 × 1013 vector genomes/kg) had a mean cFVIII activity of 7.8 
± 2.7 and 3.1 ± 1.5% of normal, respectively (Table 1; Figure 3a). 
At low dose (2 × 1013 vector genomes/kg) cFVIII plateau levels 
were 0.7 ± 0.5 and 1.7 ± 0.8% for dogs L51 and M66, respectively. 
As the dogs were not treated with cFVIII protein at the time of 
the vector infusion, cFVIII activity could be assayed immediately 
following vector administration and was detected within 1 day 
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Figure 1 comparison of canine factor VIII (cFVIII) gene constructs 
in hemophilia A mice. (a) The three best performing constructs in 
terms of expression in the hydrodynamic studies in hemophilia A mice 
(supplementary Figures s1 and s2) were selected for adeno-associated 
virus (AAV) production. Two of these constructs utilized the insulin-
like growth factor binding protein promoter/enhancer10 (IGFBP-1 and 
IGFBP-2) while one used a minimal hepatic control region-human α-1 
antitrypsin enhancer/promoter (HCR-hAAT)27. The IGFBP single-chain 
gene constructs were derived from the original 5.6 kb construct that used 
the IGFBP promoter (184 bp), two α1-microglobulin/bikunin enhancers 
(E; 100 bp) and β-globin intron (I; 175 bp). The HCR-hAAT promoter 
constructs utilize a shortened version of the hepatic control region of the 
human apolprotein ExxC-1 gene locus (E2) and a 65-bp SV40 intron (I2). 
The 5.6 kb construct used a 263-bp SV40 polyadenylation signal, while 
all of the 5.2 kb constructs used a 134-bp SV40 polyadenylation signal 
sequence. (b) Hemophilia A mice were treated with 5 × 1010vg/mouse 
of the AAV8-cFVIII-BDD constructs and compared to the original 5.6 kb 
construct. FVIII activity was determined by Coatest assay. At the 8-week 
time point, the levels of cFVIII activity as determined by Coatest were 
104 ± 21 for the original 5.6 kb construct, 116 ± 17 for the IGFBP-1, 77 ± 
30 for IGFBP-2, and 124 ± 24 for the HCR-hAAT construct. These results 
were confirmed by aPTT (data not shown). There was no significant dif-
ference between the expression levels of the IGFBP and HCR-hAAT pro-
moters in the constructs (unpaired t-test; two-tailed P = 0.45). However, 
as previously reported,35,36 the exclusion of the intron resulted in lower 
levels of expression relative to the other constructs. IGFBP10 or a minimal 
HCR-hAAT27 were used to generate the cFVIII single-chain constructs. 
The IGFBP single-chain gene constructs were derived from the original 
5.6 kb construct (Construct A) that used the insulin-like growth factor 
binding protein (IGFBP) promoter (184 bp), two α1-microglobulin/
bikunin enhancers (E; 100 bp) and β-globin intron (I; 175 bp) with an 
SV40 polyadenylation signal (Poly A1; 263 bp). The HCR-hAAT pro-
moter constructs (Construct E and J) utilize a shortened version of the 
hepatic control region of the human apolprotein ExxC-1 gene locus (E2). 
A 65-bp SV40 intron (I2) and a 134-bp SV40 polyadenylation (Poly A2) 
sequence is also used. ITR, inverted terminal repeats.
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after vector administration by shortening of the whole-blood 
clotting time (WBCT), and by Coatest within 7 days after vector 
administration. The protein was functional based on the shorten-
ing of the WBCT to 15–21 minutes (normal dog WBCT is 8–12 
minutes; Figure 3b). The cFVIII heavy- and light-chain antigen 
levels in the circulation of the single-chain dogs were equivalent 
(Table 1; Figure 4a) and were consistent with the activity lev-
els. Furthermore, we used thromboelastography for assessing 
the functional parameters of expressed FVIII (Supplementary 
Figure S3).
long-term expression after two-chain delivery 
of cFVIII in HA dogs
Our earlier studies in HA mice and dogs demonstrated that two-
chain delivery of cFVIII using AAV8 and AAV9 efficiently tar-
geted liver and resulted in therapeutic levels of circulating FVIII.5 
In this study, we expanded the dose cohorts to include additional 
HA dogs administered AAV8 and AAV9 expressing cFVIII to 
demonstrate long-term dose-dependent expression of the trans-
gene. A total of five HA dogs were administered AAV-cFVIII 
via the portal vein using two-chain delivery. One AAV8-treated 
dog (F24) and one AAV9-treated dog (H19) were previously 
described5 but long-term follow-up and additional analyses are 
presented here.
Two male dogs were coadministered AAV8-TBG-HC and 
AAV8-TBG-LC (Figure 2b). F24 was administered a high dose of 
1.25 × 1013 vector genomes/vector/kg and Linus was administered 
a low dose of 6.0 × 1012 vector genomes/vector/kg. We observed 
dose-dependent expression of cFVIII as determined by Coatest 
assay. These dogs expressed a mean value of 5.7 ± 2.3% (F24) and 
1.8 ± 0.8% (Linus; Figure 5a; Table 1). Canine FVIII was func-
tional as noted by shortening of the WBCT to near-normal levels 
(10–15 minutes) that remained consistent throughout the study 
(Figure 5b).
The dogs that were coadministered AAV9-TBG-HC and 
AAV9-TBG-LC received a similar vector dosage (Figure 5; 
Table 1). Canine FVIII levels for the dog Woodstock were com-
parable to those of AAV8-injected dogs in the high-dose cohort. 
However, in the second high-dose dog (J60), the expression levels 
were fivefold higher (Figure 5a). This dog had an unanticipated 
surgical complication that required splenectomy within minutes 
of vector administration; whether this modified the AAV9 vec-
tor delivery to the liver is unknown. The dog administered the 
low dose (H19) expressed 0.7 ± 0.6% activity that was 1.7% at the 
final time point analyzed. Taken together, these data demonstrate 
dose-dependent sustained expression of cFVIII following hepatic 
delivery of AAV8 and AAV9 vectors.
To address a potential heavy- and light-chain imbalance, we 
generated a series of monoclonal and polyclonal antibodies spe-
cific to cFVIII and developed a cFVIII enzyme-linked immuno-
sorbent assay (ELISA) for each chain.17 In contrast to single-chain 
delivery, we observed that these dogs expressed higher levels of 
antigen than would be predicted based on activity (Figure 4b). 
In fact, we detected more than four- to eightfold higher levels 
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Figure 2 canine factor VIII (cFVIII) adeno-associated virus (AAV) gene 
constructs delivered to hemophilia A dogs. (a) The single-chain con-
struct includes the 4.5 kb domain-deleted cFVIII driven by the shortened 
version of hepatic control region (HCR) of human apolprotein ExxC-1 
gene locus (192 bp) and the human α-1 antitrypsin promoter (266 bp) 
with an SV40 intron (65 bp). An SV40 polyadenylation signal (PA) is used 
(134 bp). The AAV2 inverted terminal repeats (ITRs) (145 bp) flank the 
transgene construct. The total vector size is 5.2 kb. (b) The two-chain 
delivery AAV vector approach for FVIII utilizes two separate AAV vectors 
to deliver the cFVIII complementary DNA (cDNA). One construct con-
tains the 2.5 kb heavy-chain and the second construct contains the 2.4 kb 
light-chain cDNA. Both constructs use the thyroxine-binding globulin 
gene promoter/enhancer (TBG; 695 bp) fused to an intron (175 bp) and 
an SV40 polyadenylation signal (Poly A; 263 bp). The AAV2 inverted ter-
minal repeats (ITRs; 145 bp) flank each transgene construct. The total 
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Figure 3 canine factor VIII (cFVIII) activity after single chain  delivery of 
cFVIII using adeno-associated virus 8 (AAV8) and AAV9 in  hemophilia 
A (HA) dogs. (a) Coatest assay to determine cFVIII activity after single-
chain delivery of cFVIII using AAV8 and AAV9. The solid lines represent 
dogs administered the high dose (4 × 1013vg/kg), while the dashed lines 
represent dogs administered the low dose (2 × 1013 vg/kg). The % activity 
labeled next to each data line is the average activity from all the time points 
analyzed. (b) WBCT after single chain delivery of cFVIII using AAV8 and 
AAV9. The dark gray–shaded region is the range of values for untreated HA 
dogs (>40 min), while the light gray–shaded region represents the normal 
dog values (8–12 minutes). WBCT, whole-blood clotting time.
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of heavy chain correlated closely with the activity in contrast to 
those of light chain (Table 1). The findings were similar for dogs 
injected with AAV8 or AAV9 vectors and demonstrated that the 
light chain is more abundant than the heavy chain in the circula-
tion after two-chain AAV-FVIII delivery as predicted by previous 
results in the HA mouse model.10,18
Immunological challenges with recombinant  
cFVIII-Bdd in AAV-injected HA dogs
In terms of safety, we looked for any evidence of an immune 
response to FVIII throughout the course of the study. Notably, 
before vector administration, these dogs had been exposed to 
plasma-derived cFVIII or recombinant cFVIII-BDD and none of 
these dogs had any evidence for an immune response to cFVIII; 
thus, they did not appear to be prone to inhibitor development. 
No inhibitors to cFVIII were detected in any of the two-chain dogs 
or in the high-dose cohort of the single-chain dogs. To further 
exclude the possibility of non-neutralizing  antibodies, we estab-
lished an ELISA to detect IgG antibodies specific to cFVIII and 
assessed plasma samples from the dogs for antibodies simultane-
ously with cFVIII activity measurements.17 After vector admin-
istration, no IgG1 or IgG2 antibodies to cFVIII were detected in 
any of these dogs. The only dog that had evidence of an immune 
response to cFVIII was a single-chain dog treated at the low dose 
(L51; Figure 6). Importantly, this dog had transient IgG2 anti-
bodies to FVIII until day 52 with a Bethesda titer detectable until 
day 37 (Figure 6a). No IgG1 antibodies to cFVIII were detected. 
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Figure 4 canine factor VIII (cFVIII) antigen levels after adeno-associ-
ated virus–mediated delivery of cFVIII in hemophilia A (HA) dogs. (a) 
Enzyme-linked immunosorbent assay (ELISA) to detect cFVIII heavy-chain 
(white bars) and light-chain (black bars) antigen levels at day 85 after sin-
gle-chain delivery of cFVIII. cFVIII activity for each dog at this time point 
is indicated. HA dogs have no detectable antigen and normal dogs have 
80–120 ng/ml. (b) ELISA to detect cFVIII heavy-chain (white bars) and 
light-chain (black bars) antigen levels at day 85 after two-chain delivery 
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expression in L51 coincided with the disappearance of anti-cFVIII 
antibodies (Figure 6b). Notably, the WBCT for L51 was short-
ened to 15–20 minutes throughout the study.
The sustained transgene expression and the absence of inhibi-
tors to FVIII in most of the dogs (8/9) suggest that the AAV delivery 
of cFVIII is not immunogenic. To further test this hypothesis, we 
challenged seven dogs with repeated injections of purified recom-
binant cFVIII protein17 at 1–5 years after gene transfer. No anti-
cFVIII IgG or neutralizing antibodies were detected in the dogs, 
including the dog L51 that had transient anti-cFVIII antibodies 
immediately following vector administration. The cFVIII activity 
was consistent with activity levels before the challenge. In addi-
tion, we determined that the recovery of the protein 15  minutes 
after infusion was 70 ± 12%, which was similar to observations in 
naive dogs.17 Together, we formally exclude the presence of anti-
bodies to cFVIII.
clinical outcomes after AAV vector administration
HA dogs typically have five to six spontaneous bleeding episodes 
per year that require treatment.19 In total, the nine HA dogs were 
followed for 297 months (Table 2). During this time period, we 
would expect 123 spontaneous bleeding episodes but we observed 
a total of only seven spontaneous bleeding episodes. Two addi-
tional bleeding episodes were due to hemostatic challenge caused 
by a fighting incident and a foot injury. These bleeding episodes in 
response to a hemostatic challenge such as trauma are consistent 
with observations in patients who express 1–5% of normal FVIII 
levels and require treatment under these circumstances. Notably, 
one bleeding episode occurred early after vector administration 
when the FVIII activity was not detectable. Two of the nine docu-
mented bleeding episodes in treated dogs were in high-dose ani-
mals, while seven of the nine episodes were in low-dose animals. 
Two untreated HA dogs that were followed concurrently with the 
dogs in our study had 12 bleeding episodes in 36 months. Overall, 
>90% of the expected bleeding episodes were prevented.
At the time of vector administration and throughout the 
study, clinical blood chemistries were followed (Supplementary 
Table S1). During the first week following vector administration, 
the two of the five dogs that were administered the two-chain vec-
tor via the portal vein in an open surgical procedure had mild 
elevations in liver function tests (alkaline phosphatase, alanine 
aminotransferase, and aspartate aminotransferase). In addition, 
several dogs had low platelet counts and/or hemoglobin  levels, 
perhaps due to blood loss and/or the fluids administered at the 
time of surgery. No clinical sequelae were noted (e.g., fever, inap-
petance, nausea). Thus, acute liver toxicity was observed that was 
not long term. Notably, none of the dogs treated with the single-
chain vectors via an intravenous infusion had any changes in 
blood chemistries. There was no evidence of chronic liver toxicity 
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Figure 5 canine factor VIII (cFVIII) activity after two-chain delivery of 
cFVIII using adeno-associated virus 8 (AAV8) and AAV9 in hemophilia 
A (HA) dogs. (a) Coatest assay to determine cFVIII activity after two-chain 
delivery of cFVIII using AAV8 and AAV9. The solid lines represent dogs 
administered the high dose (1.25 × 1013 vg/v/kg) while the dashed lines 
represent dogs administered the low dose (6 × 1012 vg/v/kg). The % activ-
ity labeled next to each data line is the average activity from all the time 
points analyzed. (b) WBCT after two-chain delivery of cFVIII using AAV8 
and AAV9. The dark gray–shaded region is the range of values for untreated 
HA dogs (>40 minutes), while the light gray–shaded region represents the 
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Figure 6 transient immune response to canine factor VIII (cFVIII) 
observed in l51 after administration of adeno-associated virus 8 
(AAV8)-cFVIII. (a) Anti-cFVIII IgG2 antibodies were detected by a cFVIII-
specific IgG2 enzyme-linked immunosorbent assay. No IgG1 antibod-
ies were detected. Bethesda assay detects FVIII neutralizing antibodies. 
(b) Canine FVIII activity was determined by Coatest assay.
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dIscussIon
Early phase I clinical trials using AAV vectors for the treatment of 
genetic diseases including hemophilia B hold therapeutic promises 
for HA. However, the development of AAV-based approaches for 
HA that reach therapeutic levels in large animal models of HA has 
been challenging. In this study, we demonstrate long-term dose-
dependent expression of therapeutic levels of FVIII in HA dogs 
using either a single- or two-chain delivery approach. Overall, we 
conclude that both approaches exhibit comparable, but not iden-
tical, efficacy and safety profiles. The use of novel species-specific 
reagents offers us the opportunity to characterize in detail the 
expression levels and immune responses to the neotransgene.
Therapeutic levels of FVIII were observed in all of the HA dogs 
treated with either the single- or two-chain delivery approach. 
However, only the high-dose cohorts had therapeutic levels of 
FVIII that were sustainable (Table 1). These dogs had a mild phe-
notype based on their FVIII activity and clinical phenotype. The 
low-dose cohorts were on the threshold of a moderate phenotype 
with levels of FVIII that were 0.5–2%. These FVIII levels also cor-
related with clinical observations that most of the bleeding epi-
sodes occurred in the dogs treated at low AAV doses (Table 2).
FVIII antigen level analysis found equivalent amounts of light 
and heavy chain in the circulation after single-chain delivery that 
correlate closely with the FVIII activity. The two-chain approach 
relies on cellular transduction by both the heavy- and light-chain 
vectors to generate biologically active FVIII. We observed that the 
light chain is 4–8 times more abundant than the heavy chain, which 
is a moderate imbalance compared to remarkable differences in the 
two chains reported in HA mice.18 In the dogs, the amount of FVIII 
activity correlated closely with the amount of heavy chain in the 
circulation and probably represents cells that are cotransduced. As 
FVIII is a heterodimer, this suggests that in the two-chain approach, 
the heavy chain circulates predominantly in complex with the light 
chain. In contrast, the excess amount of circulating light chain may 
be due to its inherent stabilization by von Willebrand Factor20,21 or 
differences in the cellular processing and/or secretion of the two 
chains.18 Nevertheless, both the single- and two-chain approaches 
result in biologically functional protein.
Notably, no long-term evidence for inhibitors to FVIII was 
observed in any dogs. However, a transient neutralizing antibody 
to the transgene that was observed in one dog spontaneously 
resolved within 2 months. There are several hypotheses to explain 
why this dog (L51) developed an antibody to FVIII. One hypoth-
esis is that this dog may have been prone to development of inhibi-
tors. L51 was a member of a pedigree that includes several litters 
of inhibitor prone dogs, a subcolony of HA dogs at the Chapel Hill 
dog colony that is currently being characterized.22 L51 did not have 
any evidence for anti-cFVIII antibodies before entering into this 
study. In fact, this dog had been administered recombinant cFVIII 
protein three times in an earlier study17 before vector administra-
tion. Another hypothesis is that the levels of the FVIII antigen 
were too low (<1%). In the single-chain approach, the activity 
and antigen levels are equivalent. In contrast, in the two-chain 
approach, the activity levels were low but antigen levels were more 
than fivefold higher than activity. We speculate that high antigen 
levels may avoid immune responses to the transgene even in the 
absence of activity as seen in patients with mutations, which result 
in a cross-reacting material positive phenotype. Although we did 
observe a chain imbalance in the two-chain approach, this did 
not have any measurable detrimental effects on phenotypic cor-
rection or immune response. Furthermore, the transient nature of 
the antibodies observed in L51 followed by sustained expression of 
FVIII in the absence of antibodies suggests that tolerance to FVIII 
may occur with continuous expression of FVIII after AAV admin-
istration in the liver. Supportive evidence comes from studies in 
hemophilia B mice and nonhuman primates, which demonstrated 
that hepatic delivery of AAV-FIX induces tolerance to FIX that is 
dependent on regulatory T cells.23–25 Overall, the risk of inhibitor 
development in these dogs is very low in contrast to the 20–30% 
risk in patients after protein therapy.
table 2 Frequency of bleeding episodes after AAV vector administration







of months  
evaluated
Bleeding episodes
spontaneous due to trauma total expecteda
Two-chain High F24 26 0 0 0 11
Woodstock 53 1 0 1 22
J60 39 0 0 0 16
Low Linus 51 3b 1 4 21
H19 68 1 0 1 28
Single-chain High M06 19 1 0 1 8
M50 14 0 0 0 6
Low L51 24 1 0 1 10
M66 3 0 1 1 1
Total 297 months 7 2 9 123
Untreated controls NA HA-1 24 8 0 8 10
HA-2 12 4 0 4 5
Total 36 months 12 0 12 15a
Abbreviations: AAV, adeno-associated virus; FVIII, factor VIII; HA, hemophilia A; NA, not applicable.
aExpected is five bleeding episodes per year. bOne bleed occurred early after vector administration when FVIII activity was not detectable (0%).
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Because none of the AAV-treated dogs had any evidence 
for an immune response to either plasma-derived or recombi-
nant cFVIII-BDD before AAV delivery, we challenged the dogs 
by repeated injection of recombinant cFVIII protein after vector 
injection. None of the dogs developed an immune response to 
FVIII, which is consistent with our previous report in naive HA 
dogs challenged with the same cFVIII protein.17 Notably, a dog 
with no detectable FVIII activity (H19) and another dog with no 
detectable FVIII antigen or activity (L51) at the time of the pro-
tein challenges did not develop antibodies to FVIII. Collectively, 
the data suggest that AAV-cFVIII does not increase the risk of 
antibody formation to cFVIII in noninhibitor prone dogs com-
pared to protein replacement. Furthermore, these data suggest 
that new baseline levels provided by AAV-FVIII can be achieved 
without complicating further infusion of the protein such as may 
be required to prevent bleeding during surgical procedures or 
trauma-related bleeding episodes.
The disease phenotype improved significantly when compared 
to untreated dogs followed in parallel with the experimental group 
or by estimating the expected number of bleeds per dog. We deter-
mined that >90% of the bleeds were prevented, corresponding to a 
frequency of 0.4 bleeds per year per dog. These data are in agree-
ment with the rates of 0.47 per year per person bleeding in HA boys 
undergoing intensive primary prophylaxis and in contrast to those 
boys on therapy on demand (rates of 4.9 per year per person), i.e. 
in response to bleeds.2 Further objective studies on the joint status 
in AAV-treated HA dogs and controls will be important to define 
whether there is an impact on the underlying arthropathy.
One goal of this study was to understand whether the single- 
or two-chain approach demonstrated an advantage for consider-
ation in translation to clinical application. Therapeutic levels of 
FVIII can be achieved with both approaches with similar total 
vector dosage using intravenous or portal vein delivery. In terms 
of immune responses to FVIII, it is notable that even at low anti-
gen levels, the immune response to FVIII was only transient 
and resolved spontaneously within a relatively short period of 
time as demonstrated by L51. In both approaches, there was no 
evidence of an immune response to FVIII even when activity 
is <1% of normal. In an ongoing study, we have demonstrated 
that two-chain AAV delivery induces tolerance to FVIII in dogs 
that have inhibitors to FVIII before vector administration.22 The 
administration of single chain vector in these dogs may be a 
more stringent challenge for determining the ability of that vec-
tor to induce tolerance to FVIII. Each AAV vector carries a risk 
of insertional mutagenesis26 thus in the single chain delivery the 
risk of insertional mutagenesis for particles that would not pro-
duce functional FVIII would be avoided, theoretically favoring 
this strategy.
Ongoing phase I clinical trials for AAV-mediated delivery of FIX 
for hemophilia B will provide insight as to how to move forward 
with gene therapy for HA. One trial uses AAV2-hFIX with transient 
immune suppression to avoid immune responses to AAV capsid, 
while a second trial uses AAV8 to deliver a self-complementary vec-
tor encoding FIX.15,16 Recently, data in one subject of the latter trial 
showed sustained expression of FIX at levels of 2% of normal (3 
months follow-up, ongoing observation) without immune suppres-
sion (A. Davidoff, St. Jude Children’s Research Hospital, personal 
communication, 9 September 2010). It will be important to define 
whether cytotoxic T lymphocyte responses to AAV capsid, which 
present cross-reactivity among distinct serotypes, will also hamper the 
safety of this strategy as the dose-escalation study progresses. Thus, it 
will be important to determine whether immune suppression will be 
required for AAV8 delivery. The major limitation of this study is the 
relatively high vector dose required to achieve therapeutic levels of 
FVIII. If the effectiveness of the immune suppression on the immune 
response to AAV is vector dose–dependent, then several options for 
lowering the vector dose can be explored for FVIII including the use 
of self-complementary vectors to deliver the two-chain approach,27 
introduction of tyrosine mutations in the AAV capsid to augment the 
transduction efficiency,28 and the use of codon-optimized FVIII. In 
summary, in the canine model of HA we determined that AAV-FVIII 
liver gene therapy is safe and feasible. The long-term follow-up of sus-
tainable expression of a nonimmunogenic transgene that improves 
the disease phenotype in a dose-dependent manner fulfills the basic 
requirements to support clinical application.
MAterIAls And MetHods
cFVIII transgene constructs. Two-chain cFVIII constructs were previously 
described.10 Single-chain cFVIII constructs were modified from the previ-
ously described construct (Supplementary Materials and Methods).10
AAV vector production. Recombinant AAV vectors were produced by 
triple transfection and purified by CsCl-gradient centrifugation as pre-
viously described.29 After purification, endotoxin testing was performed 
by Endochrome-K (Charles River Laboratories, Wilmington, MA) or 
Limulus Amebocyte Lysate gel-clot method (QCL-1000; Bio Whittaker, 
Walkersville, MD). Vector titers were obtained by Taqman PCR (Applied 
Biosystems, Foster City, CA). The two-chain AAV vectors were generated 
at the Penn Vector Core at The University of Pennsylvania and the single-
chain vectors were generated in the Children’s Hospital of Philadelphia 
Research Vector Core.
AAV vector administration in HA mice. Male HA exon 16 knockout mice30,31 
on a C57BL/6/129Sv background or HA exon 16/CD4 knockout mice 
were generated in our laboratory. All animal procedures were approved 
by the Institutional Animal Care and Use Committee at the University of 
Pennsylvania. AAV vectors were administered to 6- to 8-week-old male 
mice (n = 5 mice/vector) at a volume of 200 μl of phosphate-buffered 
saline/5% sorbitol via tail-vein injection. Plasma samples were collected in 
3.8% sodium citrate by tail sectioning.
AAV vector administration and recombinant protein challenges in HA 
dogs. The HA dogs are maintained at the University of North Carolina, 
Chapel Hill. All procedures in the dogs were approved by the Institutional 
Animal Care and Use Committee at the University of North Carolina. All 
of the dogs in the study were male except for J60. The two-chain AAV vec-
tors (AAV-cFVIII-HC and AAV-cFVIII-LC) were coadministered via the 
portal vein as previously described5 using 6 × 1012 and 1.25 × 1013 vec-
tor genomes/vector/kg. The animals were treated with normal dog plasma 
(150–200 cc normal dog plasma) before and immediately following vector 
administration. For intravenous administration of the single-chain AAV 
vector (2 × 1013 and 4 × 1013 vector genomes/kg), the vector was infused 
via the saphenous vein at a total volume of 10 ml/kg phosphate-buffered 
saline. This procedure did not require FVIII treatment. Hematologic and 
biochemical analysis of blood and serum samples were performed in a 
clinical pathology laboratory. For the immunologic challenges, the dogs 
were challenged with 2.5 μg/kg (25 IU/kg) of cFVIII protein one time per 
week for four consecutive weeks. Plasma samples were drawn before and 
15 minutes after each protein infusion for FVIII activity, antibody and 
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recovery analysis. Recovery analysis was determined by subtracting the 
baseline FVIII activity from the activity 15 minutes after vector infusion 
to determine the contribution of the recombinant protein to the activity 
measurements. The percent recovery of the protein was calculated based 
on the amount of infused recombinant protein (25 IU/kg).
cFVIII antigen, activity, and antibody assays. Normal canine plasma was 
used as a standard for the quantification of the cFVIII activity using the 
Chromogenix Coatest SP4 FVIII (Diapharma, Lexington, MA). WBCT 
was performed as previously described.32 Thromboelastography was per-
formed using citrated whole blood drawn and tested within 2 minutes 
after collection using thromboelastography 5000 Thromboelastograph 
Analyzer (Haemoscope, Niles, IL) according to the manufacturer’s 
instructions. The first 3 ml is discarded and 360 μl is placed per cup after 
premixing with 1 ml with kaolin. Thromboelastography recordings are 
allowed to proceed for ~90 minutes.33 cFVIII heavy- and light-chain anti-
gens were detected using a cFVIII-specific enzyme-linked immunosor-
bent assay (ELISA).17 Anti-cFVIII antibodies were detected by Bethesda 
assay34 or by cFVIII-specific IgG1 and IgG2 antibodies by ELISA.17 IgG 
ELISA and cFVIII activity measurements were performed simultaneously 
on the same plasma samples.
Statistical analysis. An unpaired two-tailed Student’s t-test was used for 
statistical analysis, with P <0.05 indicating statistical significance.
suPPleMentAry MAterIAl
Figure S1. Single chain cFVIII expression constructs.
Figure S2. Hydrodynamic delivery of pAAV-cFVIII gene constructs.
Figure S3. Thromboelastography of HA dogs after single chain 
 delivery of cFVIII.
Table S1. Clinical blood chemistries after vector administration.
Materials and Methods.
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